Drugs giant GlaxoSmithKline and German biotech firm CureVac have struck a €150m (£130m) deal to develop next-generation COVID-19 vaccines that target several variants of the virus in one product.
Source: Business – Sky News

What’s your Reaction?
+1
0
+1
0
+1
0
+1
0
+1
0
+1
0
+1
0